ArticleInternational journal of cardiology. Heart & vasculature2024
Ten-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients: The OBSERVANT study.
Article in International journal of cardiology. Heart & vasculature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Transcatheter Aortic Valve Replacement in Patients Aged 65 Years and Younger: Unresolved Issues and Future Directions.Life (Basel, Switzerland) · 2026Review
- Examining short-term and long-term outcomes in octogenarians undergoing isolated surgical aortic valve replacement.Journal of geriatric cardiology : JGC · 2026Article
- Resetting the clock: Short-term narratives and long-term realities in transcatheter valve trials.JTCVS structural and endovascular · 2026Article
- Right anterior mini-thoracotomy for isolated aortic valve replacement: An international and multicenter study.JTCVS open · 2026Article
- Ross Procedure Renaissance: A Contemporary Review of Patient Selection, Technique, and Long-Term Outcomes in Adults.Journal of the American Heart Association · 2026Review
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025Article
- Transcatheter aortic valve implantation: latest evidence, gaps in knowledge, and future directions.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Review
- Management of Asymptomatic Severe Aortic Stenosis: Current Evidence and Future Directions.Journal of clinical medicine · 2025Review
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025Article
- Five-year outcomes after surgical versus transcatheter aortic valve replacement with new generation devices from the prospective OBSERVANT studies.Cardiovascular intervention and therapeutics · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The evidence of the long-term advantages of transcatheter aortic valve replacement (TAVR) over surgical aortic valve replacement (SAVR) for aortic stenosis (AS) remains scarce. Methods: Patients with EuroSCORE II < 4 % who underwent TAVR or SAVR for AS from the prospective observational OBSERVANT study were included in this analysis. Ten-year survival was the primary outcome of this analysis. Secondary outcome was repeat procedure on the aortic valve prosthesis. Results: Propensity score matching resulted in 355 matched pairs of patients who underwent TAVR or SAVR. The mean age of SAVR patients was 80.0 ± 5.1 years and that of TAVR patients 80.1 ± 6.4 years (p = 0.81) and the mean EuroSCORE II was 2.5 ± 0.8 % and 2.6 ± 0.8 % (p = 0.60), respectively. Thirty-day mortality was 2.8 % after SAVR and 2.5 % after TAVR (p = 0.82). At 10-year, survival was 37.0 % (95 %CI 32.2-42.5 %) after SAVR and 18.2 % (95 %CI 14.5-22.8 %) after TAVR (Log-rank test, p < 0.001; HR 1.70, 95 %CI 1.42-2.03). Difference in terms of survival between the propensity matched cohorts became significant 3 years after the procedures. Ten-year cumulative incidences of repeat aortic valve procedure were 2.6 % (95 %CI 1.4-5.0 %) after SAVR and 1.1 % (95 %CI 0.4-3.0 %) after TAVR (p = 0.153; SHR 0.43, 95 %CI 0.13-1.41). Conclusions: The results of this prospective observational, non-randomized study showed that 10-year survival of low-risk patients who underwent TAVR with early generation prosthesis devices was lower than SAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.